儿童期起病的重度嗜酸性粒细胞性哮喘：贝那利珠单抗的疗效
Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab.
作者信息
Just Jocelyne, Bourgoin Melisande, Amat Flore, Cottel Nathalie, Lambert Nathalie, Wanin Stephanie
机构信息
AP-HP, Groupe hospitalier Trousseau-La Roche Guyon, Centre de l'Asthme et des Allergies, Paris, France.
Sorbonne - université, Paris, France.
出版信息
ERJ Open Res. 2020 Dec 21;6(4). doi: 10.1183/23120541.00339-2020. eCollection 2020 Oct.
Abstract
摘要
https://bit.ly/2G7Tc2k. （此为网址，无法准确翻译为中文，保留原文）
相似文献
1
Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab.儿童期起病的重度嗜酸性粒细胞性哮喘：贝那利珠单抗的疗效
ERJ Open Res. 2020 Dec 21;6(4). doi: 10.1183/23120541.00339-2020. eCollection 2020 Oct.
2
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.贝那鲁肽治疗严重、未控制哮喘患者的长期安全性和疗效：BORA 3 期扩展试验的 1 年结果。
Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8.
3
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma.
ERJ Open Res. 2021 Dec 6;7(4). doi: 10.1183/23120541.00465-2021. eCollection 2021 Oct.
4
Benralizumab: an updated treatment of eosinophilic asthma.贝那利珠单抗：一种更新的嗜酸性粒细胞性哮喘治疗方法。
Expert Rev Respir Med. 2020 May;14(5):435-444. doi: 10.1080/17476348.2020.1739526. Epub 2020 Mar 17.
5
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.血清 IgE 浓度预测重度嗜酸性粒细胞性哮喘患者恶化风险和 benralizumab 疗效的能力。
Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14.
6
Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.本那鲁单抗治疗固定气流受限和严重、未控制的嗜酸性粒细胞性哮喘患者的疗效。
Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15.
7
Benralizumab for -Negative Hypereosinophilic Syndrome.贝那利珠单抗治疗 - 阴性嗜酸性粒细胞综合征。
N Engl J Med. 2019 Apr 4;380(14):1336-1346. doi: 10.1056/NEJMoa1812185.
8
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic.重度嗜酸性粒细胞性哮喘治疗的新视野：新型精准生物制剂贝那利珠单抗
Biologics. 2019 May 22;13:89-95. doi: 10.2147/BTT.S157183. eCollection 2019.
9
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.贝那鲁肽治疗高剂量吸入性皮质激素和长效β-agonists 控制不佳的严重哮喘患者的疗效和安全性（SIROCCO）：一项随机、多中心、安慰剂对照的 3 期临床试验。
Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.
10
[A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].[一例严重哮喘因对贝那利珠单抗出现迟发性无反应而改用美泊利珠单抗的病例]
Arerugi. 2020;69(8):678-682. doi: 10.15036/arerugi.69.678.
引用本文的文献
1
Th2-High Severe Asthma with Hypereosinophilia in the Spectrum of Type 2 Inflammatory Diseases.2型炎症性疾病谱中伴有嗜酸性粒细胞增多的Th2高反应性重度哮喘
Int J Mol Sci. 2025 Jun 2;26(11):5342. doi: 10.3390/ijms26115342.
本文引用的文献
1
Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.在嗜酸性肉芽肿性多血管炎患者中使用贝那利珠单抗后髓过氧化物酶抗中性粒细胞胞浆抗体（MPO-ANCA）降低。
Allergol Int. 2019 Oct;68(4):539-540. doi: 10.1016/j.alit.2019.04.006. Epub 2019 May 9.
2
Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss).重新审视嗜酸性肉芽肿性多血管炎（Churg-Strauss）中的系统性血管炎：肺孤儿病研究和欧洲呼吸学会嗜酸性肉芽肿性多血管炎（Churg-Strauss）工作组对 157 例患者的研究。
Autoimmun Rev. 2017 Jan;16(1):1-9. doi: 10.1016/j.autrev.2016.09.018. Epub 2016 Sep 23.
3
Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort.儿童起病嗜酸性肉芽肿性多血管炎（原变应性肉芽肿性血管炎）：当代单中心队列研究。
J Rheumatol. 2013 Jun;40(6):929-35. doi: 10.3899/jrheum.120808. Epub 2013 May 1.
4
Refining the definition of hypereosinophilic syndrome.细化嗜酸性粒细胞增多综合征的定义。
J Allergy Clin Immunol. 2010 Jul;126(1):45-9. doi: 10.1016/j.jaci.2010.03.042.
5
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.MEDI-563，一种人源化抗白细胞介素-5 受体 α mAb，具有增强的抗体依赖性细胞介导的细胞毒性功能。
J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2. doi: 10.1016/j.jaci.2010.04.004.
6
IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome.白细胞介素-5通路抑制在哮喘和变应性肉芽肿性血管炎治疗中的应用
J Allergy Clin Immunol. 2010 Jun;125(6):1245-6. doi: 10.1016/j.jaci.2010.04.022.
7
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.嗜酸性粒细胞增多综合征：一项多中心回顾性分析临床特征和治疗反应。
J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3. doi: 10.1016/j.jaci.2009.09.022.
8
Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients.儿童期变应性肉芽肿性血管炎：一项系统文献综述及与成年患者的临床比较
Semin Arthritis Rheum. 2009 Oct;39(2):108-15. doi: 10.1016/j.semarthrit.2008.05.004. Epub 2008 Jul 17.
9
Treatment of patients with the hypereosinophilic syndrome with mepolizumab.使用美泊利珠单抗治疗高嗜酸性粒细胞综合征患者。
N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16.
10
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.高嗜酸性粒细胞综合征的治疗方法：研讨会总结报告
J Allergy Clin Immunol. 2006 Jun;117(6):1292-302. doi: 10.1016/j.jaci.2006.02.042. Epub 2006 May 3.
Zotero 插件